Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
39.38
+1.27 (3.33%)
At close: Dec 5, 2025, 4:00 PM EST
39.98
+0.60 (1.52%)
After-hours: Dec 5, 2025, 6:51 PM EST
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Zenas BioPharma stock have an average target of 40, with a low estimate of 19 and a high estimate of 55. The average target predicts an increase of 1.57% from the current stock price of 39.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zenas BioPharma stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $55 | Buy | Initiates | $55 | +39.66% | Nov 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $34 → $37 | Buy | Maintains | $34 → $37 | -6.04% | Nov 13, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $27 → $46 | Strong Buy | Maintains | $27 → $46 | +16.81% | Oct 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $31 → $34 | Buy | Maintains | $31 → $34 | -13.66% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $44 | Strong Buy | Maintains | $30 → $44 | +11.73% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
42.50M
from 5.00M
Increased by 750.00%
Revenue Next Year
n/a
from 42.50M
EPS This Year
-3.77
from -11.89
EPS Next Year
-4.32
from -3.77
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 89.3M | n/a | ||||
| Avg | 42.5M | n/a | ||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,685.0% | - | ||||
| Avg | 750.0% | - | ||||
| Low | 96.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.31 | -3.61 | ||||
| Avg | -3.77 | -4.32 | ||||
| Low | -5.23 | -4.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.